BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rizzetto M, Hamid S. The medical impact of hepatitis D virus infection in Asia and Africa; time for a reappraisal. Liver Int 2021;41:16-9. [DOI: 10.1111/liv.14729] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Osiowy C, Swidinsky K, Haylock-jacobs S, Sadler MD, Fung S, Wong D, Minuk GY, Doucette KE, Wong P, Tam E, Cooper C, Ramji A, Ma M, Nudo C, Tsoi K, Coffin CS. Molecular epidemiology and clinical characteristics of hepatitis D virus infection in Canada. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100461] [Reference Citation Analysis]
2 Masetti C, Aghemo A. Bulevirtide for treatment of patients with HDV infection and compensated cirrhosis: A (huge?) step in the right direction. Liver Int 2021;41:1441-2. [PMID: 34139064 DOI: 10.1111/liv.14967] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Papatheodoridi M, Papatheodoridis GV. Current status of hepatitis delta. Curr Opin Pharmacol 2021;58:62-7. [PMID: 33895531 DOI: 10.1016/j.coph.2021.03.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Rizzetto M, Stroffolini T. Forty-Five Years after the Discovery of the Hepatitis D Virus: Where Do We Stand? Viruses 2021;13:555. [PMID: 33810224 DOI: 10.3390/v13040555] [Reference Citation Analysis]